Anaphylaxis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Anaphylaxis
Emerging Therapy and TPP Insights
Thelansis’s “Anaphylaxis
Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides
a comprehensive analysis of the emerging competitive landscape, unmet needs,
target product profiles (TPPs), trial designs, and KOL insights on key emerging
therapies and key drug development opportunities in the indication.
Anaphylaxis
Overview
Anaphylaxis is defined as a sudden and
potentially life-threatening allergic reaction that affects the entire body. It
occurs when a foreign substance triggers a response with specific IgE
antibodies on mast cells and basophils in the blood. This interaction leads to
the release of histamine and other chemicals, causing various symptoms such as
muscle spasms, bronchospasm, swelling of mucous membranes, inflammation, and
increased permeability of blood vessels. The symptoms of anaphylaxis can range
from respiratory difficulties and severe hives to low blood pressure and
swelling of the deeper layers of the skin. Despite extensive research, there is
currently no single biomarker that definitively confirms an anaphylactic
reaction. Further research is needed to identify biomarkers specific to
different types of anaphylaxis, which would help determine severity, predict
risks, and choose the most effective treatment for each patient. Various
factors, including individual risk factors and co-factors, can influence the
severity and onset of anaphylaxis. Identifying these factors is crucial for
implementing preventive measures and reducing the likelihood of recurrence.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Read more: Anaphylaxis – Emerging Therapy, with Unmet Needs and
TPP Insights Report – 2025
Comments
Post a Comment